Skip to main content
Erschienen in: Drug Safety 3/2000

01.09.2000 | Review Article

Cardiovascular Adverse Effects of Antipsychotic Drugs

verfasst von: Dr Nicholas A. Buckley, Prashanthan Sanders

Erschienen in: Drug Safety | Ausgabe 3/2000

Einloggen, um Zugang zu erhalten

Abstract

Minor cardiovascular adverse effects from antipsychotic drugs are extremely common. They include effects such as postural hypotension and tachycardia due to anticholinergic or α1-adrenoceptor blockade, and may occur in the majority of patients at therapeutic dosages. There are a number of pharmacological effects that are of uncertain clinical significance, such as blockade of calmodulin, sodium and calcium channels and α2-adrenoceptors in the central nervous system. The most serious consequences of treatment, arrhythmias and sudden death, are probably uncommon and are most likely to be caused primarily by blockade of cardiac potassium channels such as HERG. Incomplete evidence suggests that arrhythmias and sudden death are a particular problem with certain drugs (thioridazine and droperidol), high risk populations (elderly, pre-existing cardiovascular disease, inherited disorders of cardiac ion channels or of antipsychotic drug metabolism) or people taking interacting drugs (such as drugs that prolong the QT interval, e.g. tricyclic antidepressants, drugs that inhibit antipsychotic drug metabolism, or diuretics). Clozapine may be unique in also causing death from myocarditis and cardiomyopathy. Much further research is required to more clearly identify high risk drugs and the populations that are at risk of sudden death, as well as the mechanisms involved and the extent of the risk.
Literatur
1.
Zurück zum Zitat Mehtonen OP, Aranko K, Malkonen L, et al. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991; 84(1): 58–64PubMedCrossRef Mehtonen OP, Aranko K, Malkonen L, et al. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991; 84(1): 58–64PubMedCrossRef
2.
Zurück zum Zitat Kelly HG, Kay JE, Laverty SG. Thioridazine HCL (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can Med Assoc J 1963; 89: 546–53PubMed Kelly HG, Kay JE, Laverty SG. Thioridazine HCL (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can Med Assoc J 1963; 89: 546–53PubMed
3.
Zurück zum Zitat Working Group of the Royal College of Psychiatrists’ Psychopharmacology Sub-Group. The association between antipsychotic drugs and sudden death [CR 57]. Council report. London: Royal College of Psychiatrists, 1997 Working Group of the Royal College of Psychiatrists’ Psychopharmacology Sub-Group. The association between antipsychotic drugs and sudden death [CR 57]. Council report. London: Royal College of Psychiatrists, 1997
4.
Zurück zum Zitat Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82(4): 1106–16PubMedCrossRef Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82(4): 1106–16PubMedCrossRef
5.
Zurück zum Zitat Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348(9019): 7–12 Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348(9019): 7–12
6.
Zurück zum Zitat Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324(12): 781–8PubMedCrossRef Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324(12): 781–8PubMedCrossRef
7.
Zurück zum Zitat Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992; 327 (4): 227–33 Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992; 327 (4): 227–33
8.
Zurück zum Zitat Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325–9PubMedCrossRef Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325–9PubMedCrossRef
9.
Zurück zum Zitat Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998; 59 Suppl. 12: 17–22 Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998; 59 Suppl. 12: 17–22
10.
Zurück zum Zitat Daly JM, Goldberg RJ, Braman SS. Polyserositis associated with clozapine treatment. Am J Psychiatry 1992; 149(9): 1274–5PubMed Daly JM, Goldberg RJ, Braman SS. Polyserositis associated with clozapine treatment. Am J Psychiatry 1992; 149(9): 1274–5PubMed
11.
Zurück zum Zitat Kilian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841–5PubMedCrossRef Kilian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841–5PubMedCrossRef
12.
Zurück zum Zitat Neeper R, Richelson E, Nelson A. Neuroleptic binding to muscarinic M2 receptors of normal human heart in vitro and comparison with binding to M1 and dopamine D2 receptors of brain. Neuropharmacology 1991; 30(5): 527–9PubMedCrossRef Neeper R, Richelson E, Nelson A. Neuroleptic binding to muscarinic M2 receptors of normal human heart in vitro and comparison with binding to M1 and dopamine D2 receptors of brain. Neuropharmacology 1991; 30(5): 527–9PubMedCrossRef
13.
Zurück zum Zitat Huikuri HV, Makikallio T, Airaksinen KE, et al. Measurement of heart rate variability: a clinical tool or a research toy? J Am Coll Cardiol 1999; 34(7): 1878–83PubMedCrossRef Huikuri HV, Makikallio T, Airaksinen KE, et al. Measurement of heart rate variability: a clinical tool or a research toy? J Am Coll Cardiol 1999; 34(7): 1878–83PubMedCrossRef
14.
Zurück zum Zitat Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998; 98(15): 1510–6PubMedCrossRef Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998; 98(15): 1510–6PubMedCrossRef
15.
Zurück zum Zitat Tuininga YS, van Veldhuisen DJ, Brouwe J, et al. Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment. Br Heart J 1994; 72(6): 509–13PubMedCrossRef Tuininga YS, van Veldhuisen DJ, Brouwe J, et al. Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment. Br Heart J 1994; 72(6): 509–13PubMedCrossRef
16.
Zurück zum Zitat Huikuri HV, Jokinen V, Syvanne M, et al. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1999; 19(8): 1979–85PubMedCrossRef Huikuri HV, Jokinen V, Syvanne M, et al. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1999; 19(8): 1979–85PubMedCrossRef
17.
Zurück zum Zitat Zahn TP, Pickar D. Autonomic effects of clozapine in schizophrenia: comparison with placebo and fluphenazine. Biol Psychiatry 1993; 34(1-2): 3–12PubMedCrossRef Zahn TP, Pickar D. Autonomic effects of clozapine in schizophrenia: comparison with placebo and fluphenazine. Biol Psychiatry 1993; 34(1-2): 3–12PubMedCrossRef
18.
Zurück zum Zitat Agelink MW, Malessa R, Kamcili E, et al. Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: a potential predictor of short-term outcome? Neuropsychobiology 1998; 38(1): 19–24PubMedCrossRef Agelink MW, Malessa R, Kamcili E, et al. Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: a potential predictor of short-term outcome? Neuropsychobiology 1998; 38(1): 19–24PubMedCrossRef
19.
Zurück zum Zitat Rechli T, Bec G, Wei M, et al. Correlation between plasma clozapine concentration and heart rate variability in schizophrenic patients. Psychopharmacol Berl 1998; 135(4): 338–41CrossRef Rechli T, Bec G, Wei M, et al. Correlation between plasma clozapine concentration and heart rate variability in schizophrenic patients. Psychopharmacol Berl 1998; 135(4): 338–41CrossRef
20.
Zurück zum Zitat Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316(7): 363–9PubMedCrossRef Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316(7): 363–9PubMedCrossRef
21.
Zurück zum Zitat Thapa PB, Gideon P, Fought RL, et al. Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents. Am J Epidemiol 1995; 142(2): 202–11PubMed Thapa PB, Gideon P, Fought RL, et al. Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents. Am J Epidemiol 1995; 142(2): 202–11PubMed
22.
23.
Zurück zum Zitat Ackerman MJ. The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc 1998; 73(3): 250–69PubMedCrossRef Ackerman MJ. The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc 1998; 73(3): 250–69PubMedCrossRef
24.
Zurück zum Zitat Taglialatela M, Castaldo P, Pannaccione A, et al. Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: present and future implications. Biochem Pharmacol 1998; 55(11): 1741–6PubMedCrossRef Taglialatela M, Castaldo P, Pannaccione A, et al. Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: present and future implications. Biochem Pharmacol 1998; 55(11): 1741–6PubMedCrossRef
25.
Zurück zum Zitat Suessbrich H, Schonherr R, Heinemann H, et al. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 1997; 120(5): 968–74PubMedCrossRef Suessbrich H, Schonherr R, Heinemann H, et al. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 1997; 120(5): 968–74PubMedCrossRef
26.
Zurück zum Zitat Rampe D, Murawsky MK, Gra J, et al. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998; 286(2): 788–93PubMed Rampe D, Murawsky MK, Gra J, et al. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998; 286(2): 788–93PubMed
27.
Zurück zum Zitat Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes: mechanisms and management. Drugs 1994; 47(1): 51–65PubMedCrossRef Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes: mechanisms and management. Drugs 1994; 47(1): 51–65PubMedCrossRef
28.
Zurück zum Zitat Eckardt L, Haverkamp W, Borggrefe M, et al. Experimental models of torsade de pointes. Cardiovasc Res 1998; 39(1): 178–93PubMedCrossRef Eckardt L, Haverkamp W, Borggrefe M, et al. Experimental models of torsade de pointes. Cardiovasc Res 1998; 39(1): 178–93PubMedCrossRef
29.
Zurück zum Zitat Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation 1999; 99(4): 518–28PubMedCrossRef Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation 1999; 99(4): 518–28PubMedCrossRef
30.
Zurück zum Zitat Bazett HC. An analysis of the time relations of electrocardiograms. Heart 1920; 7: 353–70 Bazett HC. An analysis of the time relations of electrocardiograms. Heart 1920; 7: 353–70
31.
Zurück zum Zitat Viskin S, Belhassen B. Polymorphic ventricular tachyarrhythmias in the absence of organic heart disease: classification, differential diagnosis, and implications for therapy. Prog Cardiovasc Dis 1998; 41(1): 17–34PubMedCrossRef Viskin S, Belhassen B. Polymorphic ventricular tachyarrhythmias in the absence of organic heart disease: classification, differential diagnosis, and implications for therapy. Prog Cardiovasc Dis 1998; 41(1): 17–34PubMedCrossRef
32.
Zurück zum Zitat Ogata N, Narahashi T. Block of sodium channels by psychotropic drugs in single guinea-pig cardiac myocytes. Br J Pharmacol 1989; 97(3): 905–13PubMedCrossRef Ogata N, Narahashi T. Block of sodium channels by psychotropic drugs in single guinea-pig cardiac myocytes. Br J Pharmacol 1989; 97(3): 905–13PubMedCrossRef
33.
Zurück zum Zitat Somberg JC. Clinical use of class 1c antiarrhythmic drugs. In: Vaughan Williams EM, editor. Antiarrhythmic drugs. Berlin: Springer-Verlag, 1989: 235–77CrossRef Somberg JC. Clinical use of class 1c antiarrhythmic drugs. In: Vaughan Williams EM, editor. Antiarrhythmic drugs. Berlin: Springer-Verlag, 1989: 235–77CrossRef
34.
Zurück zum Zitat Brugad P, Brugad J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20(6): 1391–6CrossRef Brugad P, Brugad J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20(6): 1391–6CrossRef
35.
Zurück zum Zitat Brugad J, Brugad P. Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. J Cardiovasc Electrophysiol 1997; 8(3): 325–31CrossRef Brugad J, Brugad P. Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. J Cardiovasc Electrophysiol 1997; 8(3): 325–31CrossRef
36.
Zurück zum Zitat Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle-branch block but structurally normal hearts. Circulation 2000; 101: 510–5PubMedCrossRef Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle-branch block but structurally normal hearts. Circulation 2000; 101: 510–5PubMedCrossRef
37.
Zurück zum Zitat Chen Q, Kirsch GE, Zhang D, et al. Genetic basis andmolecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392(6673): 293–6PubMedCrossRef Chen Q, Kirsch GE, Zhang D, et al. Genetic basis andmolecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392(6673): 293–6PubMedCrossRef
38.
Zurück zum Zitat Veldkamp MW, Viswanathan PC, Bezzina C, et al. Two distinct congenital arrhythmias evoked by a multidysfunctional Na+ channel. Circ Res 2000; 86: 91–7eCrossRef Veldkamp MW, Viswanathan PC, Bezzina C, et al. Two distinct congenital arrhythmias evoked by a multidysfunctional Na+ channel. Circ Res 2000; 86: 91–7eCrossRef
39.
Zurück zum Zitat Bezzina C, Veldkamp MW, van Den Berg MP, et al. A single Na+ channel mutation causing both long-QT and Brugada syndromes. Circ Res 1999; 85(12): 1206–13PubMedCrossRef Bezzina C, Veldkamp MW, van Den Berg MP, et al. A single Na+ channel mutation causing both long-QT and Brugada syndromes. Circ Res 1999; 85(12): 1206–13PubMedCrossRef
40.
Zurück zum Zitat Sanders P, Farouque O, Cehic DA, et al. An unusual cause of arrhythmic syncope: the Brugada syndrome. Aust NZ J Med 1999; 29: 737–8CrossRef Sanders P, Farouque O, Cehic DA, et al. An unusual cause of arrhythmic syncope: the Brugada syndrome. Aust NZ J Med 1999; 29: 737–8CrossRef
41.
Zurück zum Zitat Tohyou Y, Nakazawa K, Ozawa N, et al. A survey in the incidence of right bundle branch block with ST elevation among normal population. Jpn J Electrocardiol 1995; 15: 223–6CrossRef Tohyou Y, Nakazawa K, Ozawa N, et al. A survey in the incidence of right bundle branch block with ST elevation among normal population. Jpn J Electrocardiol 1995; 15: 223–6CrossRef
42.
Zurück zum Zitat Brugada P, Brugada R, Brugada J, et al. Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts. Am J Cardiol 1999; 83(5B): 98–100DCrossRef Brugada P, Brugada R, Brugada J, et al. Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts. Am J Cardiol 1999; 83(5B): 98–100DCrossRef
43.
Zurück zum Zitat Scheinman MM. Is the Brugada syndrome a distinct clinical entity? J Cardiovasc Electrophysiol 1997; 8(3): 332–6PubMedCrossRef Scheinman MM. Is the Brugada syndrome a distinct clinical entity? J Cardiovasc Electrophysiol 1997; 8(3): 332–6PubMedCrossRef
44.
Zurück zum Zitat Chevalier S, Buckley NA, O’Connell DL, et al. ECG predictors of arrhythmias after tricyclic and thioridazine overdose [abstract]. Aust NZ J Med 1995; 25: 625 Chevalier S, Buckley NA, O’Connell DL, et al. ECG predictors of arrhythmias after tricyclic and thioridazine overdose [abstract]. Aust NZ J Med 1995; 25: 625
45.
Zurück zum Zitat Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999; 10(2): 272–82PubMedCrossRef Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999; 10(2): 272–82PubMedCrossRef
46.
Zurück zum Zitat Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92(5): 1326–31PubMedCrossRef Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92(5): 1326–31PubMedCrossRef
47.
Zurück zum Zitat Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274(8): 620–5PubMedCrossRef Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274(8): 620–5PubMedCrossRef
48.
Zurück zum Zitat Hansen JF. Review of postinfarct treatment with verapamil: combined experience of early and late intervention studies with verapamil in patients with acute myocardial infarction. Danish Study Group on Verapamil in Myocardial Infarction. Cardiovasc Drugs Ther 1994; 8Suppl. 3: 543–7PubMedCrossRef Hansen JF. Review of postinfarct treatment with verapamil: combined experience of early and late intervention studies with verapamil in patients with acute myocardial infarction. Danish Study Group on Verapamil in Myocardial Infarction. Cardiovasc Drugs Ther 1994; 8Suppl. 3: 543–7PubMedCrossRef
49.
Zurück zum Zitat Hull BE, Lockwood TD. Toxic cardiomyopathy: the effect of antipsychotic-antidepressant drugs and calcium on myocardial protein degradation and structural integrity. Toxicol Appl Pharmacol 1986; 86(2): 308–24PubMedCrossRef Hull BE, Lockwood TD. Toxic cardiomyopathy: the effect of antipsychotic-antidepressant drugs and calcium on myocardial protein degradation and structural integrity. Toxicol Appl Pharmacol 1986; 86(2): 308–24PubMedCrossRef
50.
Zurück zum Zitat Thorogood M, Cowen P, Mann J, et al. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet 1992; 340(8827): 1067–8PubMedCrossRef Thorogood M, Cowen P, Mann J, et al. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet 1992; 340(8827): 1067–8PubMedCrossRef
51.
Zurück zum Zitat Psychotropic drugs andmyocardial infarction: cause for or caused by panic [editorial]? Lancet 1992; 340 (8827): 1069–70 Psychotropic drugs andmyocardial infarction: cause for or caused by panic [editorial]? Lancet 1992; 340 (8827): 1069–70
52.
Zurück zum Zitat Lejoyeux M, Maziere JC. Could the interaction of neuroleptics with calmodulin be an ‘explanation’ of the psychotropic effects? Encephale 1991; 17(1): 11–5PubMed Lejoyeux M, Maziere JC. Could the interaction of neuroleptics with calmodulin be an ‘explanation’ of the psychotropic effects? Encephale 1991; 17(1): 11–5PubMed
53.
Zurück zum Zitat Otani H, Engelman RM, Rousou JA, et al. Improvement of myocardial function by trifluoperazine, a calmodulin antagonist, after acute coronary artery occlusion and coronary revascularization. J Thorac Cardiovasc Surg 1989; 97(2): 267–74PubMed Otani H, Engelman RM, Rousou JA, et al. Improvement of myocardial function by trifluoperazine, a calmodulin antagonist, after acute coronary artery occlusion and coronary revascularization. J Thorac Cardiovasc Surg 1989; 97(2): 267–74PubMed
54.
Zurück zum Zitat Leo RJ, Kreeger JL, Kim KY. Cardiomyopathy associated with clozapine. Ann Pharmacother 1996; 30(6): 603–5PubMed Leo RJ, Kreeger JL, Kim KY. Cardiomyopathy associated with clozapine. Ann Pharmacother 1996; 30(6): 603–5PubMed
55.
Zurück zum Zitat Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355(9209): 1048–52PubMedCrossRef Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355(9209): 1048–52PubMedCrossRef
56.
Zurück zum Zitat Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 1997; 31(7-8): 867–70PubMed Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 1997; 31(7-8): 867–70PubMed
57.
Zurück zum Zitat Black JL, Richelson E. Antipsychotic drugs: prediction of side-effect profiles based on neuroreceptor data derived from human brain tissue. Mayo Clin Proc 1987; 62(5): 369–72PubMed Black JL, Richelson E. Antipsychotic drugs: prediction of side-effect profiles based on neuroreceptor data derived from human brain tissue. Mayo Clin Proc 1987; 62(5): 369–72PubMed
58.
Zurück zum Zitat Richelso E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60Suppl. 10: 5–14 Richelso E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60Suppl. 10: 5–14
59.
Zurück zum Zitat Studenik C, Lemmens-Gruber R, Heistracher P. Proarrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers. Eur J Pharm Sci 1999; 7(2): 113–8PubMedCrossRef Studenik C, Lemmens-Gruber R, Heistracher P. Proarrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers. Eur J Pharm Sci 1999; 7(2): 113–8PubMedCrossRef
60.
Zurück zum Zitat Silver H, Kogan H, Zlotogorski D. Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry 1990; 51(11): 459–62PubMed Silver H, Kogan H, Zlotogorski D. Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry 1990; 51(11): 459–62PubMed
61.
Zurück zum Zitat Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 1996; 93(4): 311–3PubMedCrossRef Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 1996; 93(4): 311–3PubMedCrossRef
62.
Zurück zum Zitat Kitayama H, Kiuchi K, Nejima J, et al. Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease. Eur J Clin Pharmacol 1999; 55(4): 259–62PubMedCrossRef Kitayama H, Kiuchi K, Nejima J, et al. Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease. Eur J Clin Pharmacol 1999; 55(4): 259–62PubMedCrossRef
63.
Zurück zum Zitat Jusic N, Lader M. Post-mortem antipsychotic drug concentrations and unexplained deaths. Br J Psychiatry 1994; 165(6): 787–91PubMedCrossRef Jusic N, Lader M. Post-mortem antipsychotic drug concentrations and unexplained deaths. Br J Psychiatry 1994; 165(6): 787–91PubMedCrossRef
64.
Zurück zum Zitat Barnes TR, McPhillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry 1999; 174Suppl. 38: 34–43 Barnes TR, McPhillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry 1999; 174Suppl. 38: 34–43
65.
Zurück zum Zitat Hartigan-Go K, Bateman DN, Nyberg G, et al. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996; 60(5): 543–53PubMedCrossRef Hartigan-Go K, Bateman DN, Nyberg G, et al. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996; 60(5): 543–53PubMedCrossRef
66.
Zurück zum Zitat Sharma ND, Rosman HS, Padhi ID, et al. Torsade de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81(2): 238–40PubMedCrossRef Sharma ND, Rosman HS, Padhi ID, et al. Torsade de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81(2): 238–40PubMedCrossRef
67.
Zurück zum Zitat Low RAJ, Fuller MA, Popli A. Clozapine induced atrial fibrillation [letter]. J Clin Psychopharmacol 1998; 18(2): 170PubMedCrossRef Low RAJ, Fuller MA, Popli A. Clozapine induced atrial fibrillation [letter]. J Clin Psychopharmacol 1998; 18(2): 170PubMedCrossRef
68.
Zurück zum Zitat Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 1995; 33(3): 199–204PubMedCrossRef Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 1995; 33(3): 199–204PubMedCrossRef
69.
Zurück zum Zitat Parsons M, Buckley NA. Antipsychotic drugs in overdose: practical management guidelines. CNS Drugs 1997; 6(6): 427–41CrossRef Parsons M, Buckley NA. Antipsychotic drugs in overdose: practical management guidelines. CNS Drugs 1997; 6(6): 427–41CrossRef
70.
Zurück zum Zitat Buckley N, McManus P. Fatal toxicity of drugs used in the treatment of psychotic illnesses. Br J Psychiatry 1998; 172: 461–4PubMedCrossRef Buckley N, McManus P. Fatal toxicity of drugs used in the treatment of psychotic illnesses. Br J Psychiatry 1998; 172: 461–4PubMedCrossRef
71.
Zurück zum Zitat von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991; 49(3): 234–40CrossRef von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991; 49(3): 234–40CrossRef
72.
Zurück zum Zitat Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999; 99(4): 529–33PubMedCrossRef Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999; 99(4): 529–33PubMedCrossRef
73.
Zurück zum Zitat Cohen BM, Sommer BR. Metabolism of thioridazine in the elderly. J Clin Psychopharmacol 1988; 8(5): 336–9PubMedCrossRef Cohen BM, Sommer BR. Metabolism of thioridazine in the elderly. J Clin Psychopharmacol 1988; 8(5): 336–9PubMedCrossRef
74.
Zurück zum Zitat Cohen BM, Lipinski JF, Waternaux C. Afixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites. Psychopharmacol Berl 1989; 97(4): 481–8CrossRef Cohen BM, Lipinski JF, Waternaux C. Afixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites. Psychopharmacol Berl 1989; 97(4): 481–8CrossRef
75.
Zurück zum Zitat Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 1997; 17(3): 531–7PubMed Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 1997; 17(3): 531–7PubMed
76.
Zurück zum Zitat Javaid JI. Clinical pharmacokinetics of antipsychotics. J Clin Pharmacol 1994; 34(4): 286–95PubMed Javaid JI. Clinical pharmacokinetics of antipsychotics. J Clin Pharmacol 1994; 34(4): 286–95PubMed
77.
Zurück zum Zitat Meyer MC, Baldessarini RJ, Goff DC, et al. Clinically significant interactions of psychotropic agents with antipsychotic drugs. Drug Saf 1996; 15(5): 333–46PubMedCrossRef Meyer MC, Baldessarini RJ, Goff DC, et al. Clinically significant interactions of psychotropic agents with antipsychotic drugs. Drug Saf 1996; 15(5): 333–46PubMedCrossRef
78.
Zurück zum Zitat Markowitz JS, Wells BG, Carson WH. Interactions between antipsychotic and antihypertensive drugs. Ann Pharmacother 1995; 29(6): 603–9PubMed Markowitz JS, Wells BG, Carson WH. Interactions between antipsychotic and antihypertensive drugs. Ann Pharmacother 1995; 29(6): 603–9PubMed
79.
Zurück zum Zitat Appleby L, Thomas S, Ferrier N, et al. Sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2000; 176: 405–6PubMedCrossRef Appleby L, Thomas S, Ferrier N, et al. Sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2000; 176: 405–6PubMedCrossRef
80.
Zurück zum Zitat Hale PWJ, Poklis A. Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart. Toxicol Appl Pharmacol 1986; 86(1): 44–55PubMedCrossRef Hale PWJ, Poklis A. Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart. Toxicol Appl Pharmacol 1986; 86(1): 44–55PubMedCrossRef
Metadaten
Titel
Cardiovascular Adverse Effects of Antipsychotic Drugs
verfasst von
Dr Nicholas A. Buckley
Prashanthan Sanders
Publikationsdatum
01.09.2000
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 3/2000
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200023030-00004

Weitere Artikel der Ausgabe 3/2000

Drug Safety 3/2000 Zur Ausgabe